On August 12, PICC Property and Casualty Company Limited, a subsidiary of People's Insurance Company (Group) of China Limited (01339), announced it has underwritten the country's first invasive brain-computer interface (BCI) surgery accident insurance policy for the Second Affiliated Hospital of Zhejiang University School of Medicine.
This initiative fills a critical gap in domestic risk protection, exploring a new collaborative model of "technological innovation + medical application + insurance coverage" to serve the nation's future industrial strategy through insurance expertise.
Invasive BCI surgery involves implanting microelectrodes deep within the cerebral cortex, a highly precise and complex procedure that carries specific risks such as intraoperative trauma, postoperative infections, and diagnostic or treatment errors. To address these industry challenges, PICC P&C has custom-developed a BCI surgery accident insurance policy that comprehensively covers exclusive risk scenarios, including intraoperative accidents, postoperative complications, and medical negligence.
This insurance can form a multi-tiered, complementary protection system alongside basic medical insurance and inclusive health insurance, achieving a two-way safety net: easing the risk burden for severely ill patients undergoing cutting-edge innovative treatments and reducing their treatment concerns, while also providing a risk cushion for medical institutions performing high-precision BCI clinical surgeries, thereby lowering barriers to the clinical adoption of advanced technology.
Brain-computer interfaces are one of six future industries included in the national "15th Five-Year Plan" and represent a strategically vital frontier where life sciences deeply integrate with information technology. By leveraging bidirectional information exchange between the brain and external devices, this technology can establish new pathways for treatment, rehabilitation, and functional compensation for patients with severe conditions such as spinal cord injuries, severe motor dysfunction, and neurodegenerative diseases, making it a core technological track for cultivating new productive forces.
Before this specialized insurance was introduced, there was no corresponding dedicated risk protection in China, which had become a prominent bottleneck in transitioning BCI technology from the laboratory to clinical application and large-scale industrial use. This first policy issuance not only addresses the risk protection shortfall in the clinical translation phase of future industries but also leverages the insurance industry's professional risk management capabilities to unlock the complete "research–clinical–industrialization" chain, accelerating the practical application of cutting-edge technological achievements.
Furthermore, it fulfills the social responsibility of a central financial enterprise, empowering the high-quality development of the broader health industry by focusing on the core function of insurance, safeguarding people's lives and health, and effectively playing a vital role in social protection.